ArticleEndocrine-related cancer2011
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.
Article in Endocrine-related cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.PloS one · 2017Pooled it
- Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.PloS one · 2014Trial
- Hypomethylation-mediated overexpression of ITGA2 stimulates cell invasion and migration of thyroid carcinoma.Histology and histopathology · 2023Article
- Association of DNA Promoter Methylation andCurrent oncology (Toronto, Ont.) · 2023Article
- Induction of the BRAFV600E Mutation in Thyroid Cells Leads to Frequent Hypermethylation.Clinical and experimental otorhinolaryngology · 2022Article
- Preliminary Study on the Sequencing of Whole Genomic Methylation and Transcriptome-Related Genes in Thyroid Carcinoma.Cancers · 2022Article
- Molecular Markers Guiding Thyroid Cancer Management.Cancers · 2020Review
- Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy.Cancer biology & medicine · 2019Article
- DNA methylation alterations as therapeutic prospects in thyroid cancer.Journal of endocrinological investigation · 2019Review
- Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression.Cell death & disease · 2019Article
- Methylation of tumour suppressor genes associated with thyroid cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance.Endocrine connections · 2018Article
- Methylome profiling of healthy and central precocious puberty girls.Clinical epigenetics · 2018Article
- Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.Clinical epigenetics · 2018Article
- HORMAD2 methylation-mediated epigenetic regulation of gene expression in thyroid cancer.Journal of cellular and molecular medicine · 2018Article
- Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.Nature communications · 2018Article
- Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.Molecular diagnosis & therapy · 2018Review
- Active Surveillance for Papillary Thyroid Microcarcinoma: Challenges and Prospects.Frontiers in endocrinology · 2018Review
- Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia.Epigenetics · 2018Article
- Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The BRAF V600E mutation plays an important role in the tumorigenesis of papillary thyroid cancer (PTC). To explore an epigenetic mechanism involved in this process, we performed a genome-wide DNA methylation analysis using a methylated CpG island amplification (MCA)/CpG island microarray system to examine gene methylation alterations after shRNA knockdown of BRAF V600E in thyroid cancer cells. Our results revealed numerous methylation targets of BRAF V600E mutation with a large cohort of hyper- or hypo-methylated genes in thyroid cancer cells, which are known to have important metabolic and cellular functions. As hypomethylation of numerous genes by BRAF V600E was particularly a striking finding, we took a further step to examine the selected 59 genes that became hypermethylated in both cell lines upon BRAF V600E knockdown and found them to be mostly correspondingly under-expressed (i.e. they were normally maintained hypomethylated and over-expressed by BRAF V600E in thyroid cancer cells). We confirmed the methylation status of selected genes revealed on MCA/CpG microarray analysis by performing methylation-specific PCR. To provide proof of concept that some of the genes uncovered here may play a direct oncogenic role, we selected six of them to perform shRNA knockdown and examined its effect on cellular functions. Our results demonstrated that the HMGB2 gene played a role in PTC cell proliferation and the FDG1 gene in cell invasion. Thus, this study uncovered a prominent epigenetic mechanism through which BRAF V600E can promote PTC tumorigenesis by altering the methylation and hence the expression of numerous important genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.